CAI
Caris Life Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.07
−0.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 989.6M | 812.0M | 412.3M | 306.1M | 258.5M |
| Cost of Revenue | 300.2M | 272.9M | 233.5M | 216.8M | 178.5M |
| Gross Profit | 689.4M | 539.2M | 178.8M | 89.3M | 80.0M |
| Operating Expenses | |||||
| R&D Expense | 91.2M | 45.3M | 113.9M | 116.9M | 101.3M |
| SG&A Expense | 419.0M | 392.5M | 321.9M | 291.5M | 294.5M |
| General & Admin Expense | 234.7M | 225.0M | 173.6M | 152.0M | 156.2M |
| Selling & Marketing Expense | 184.2M | 167.5M | 148.3M | 139.5M | 138.4M |
| Other Expenses | 25.9M | 56.3M | 128.0K | 500.0K | — |
| Total Operating Expenses | 536.1M | 494.1M | 435.9M | 408.9M | 395.8M |
| Cost and Expenses | 836.3M | 766.9M | 669.4M | 625.7M | 574.2M |
| Operating Income (EBIT) | 153.3M | 45.1M | (257.1M) | (319.6M) | (315.8M) |
| Non-Operating | |||||
| Interest Income | 28.0M | 16.5M | 7.1M | 11.3M | 947.0K |
| Interest Expense | 46.9M | 56.9M | 50.0M | 31.6M | 26.7M |
| Net Interest Income | (18.9M) | (40.4M) | (42.9M) | (20.4M) | (25.7M) |
| Other Non-Op Income/Expense | (48.2M) | (113.2M) | (24.8M) | (21.9M) | (5.1M) |
| Non-Operating Income (excl Interest) | 1.3M | 56.3M | (25.3M) | (9.7M) | (21.6M) |
| EBT (Pre-Tax Income) | 105.0M | (68.1M) | (281.9M) | (341.4M) | (320.8M) |
| Income Tax Expense | (111.0K) | 469.9M | — | — | — |
| Bottom Line | |||||
| Net Income | 105.1M | (538.0M) | (281.9M) | (341.4M) | (320.8M) |
| Earnings from Cont. Ops | 105.1M | (538.0M) | (281.9M) | (341.4M) | (320.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 105.1M | (538.0M) | (688.4M) | (462.5M) | (399.8M) |
| Per Share | |||||
| Basic EPS | $0.37 | ($1.91) | ($2.70) | ($1.82) | ($1.57) |
| Diluted EPS | $0.36 | ($1.86) | ($2.70) | ($1.82) | ($1.57) |
| Revenue Per Share | $3.50 | $2.88 | $1.62 | $1.20 | $1.01 |
| Shares | |||||
| Basic Shares Outstanding | 282.9M | 282.3M | 254.7M | 254.7M | 254.8M |
| Diluted Shares Outstanding | 282.9M | 289.9M | 254.7M | 254.7M | 254.8M |
| Profitability Metrics | |||||
| EBITDA | 172.7M | 11.4M | (183.0M) | (260.8M) | (245.9M) |
| D&A | 20.8M | 22.6M | 48.9M | 49.0M | 48.3M |
| EBIT | 151.9M | (11.2M) | (231.9M) | (309.8M) | (294.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026